Aldeyra Therapeutics Posts Wider Q2 Loss
1:51PM ET 8/05/2022 MT NewswiresAldeyra Therapeutics (ALDX) reported Friday a Q2 net loss per share of $0.30, widening from a loss of $0.28 a year earlier. Analysts polled by Capital IQ...
Aldeyra Therapeutics (ALDX) reported Friday a Q2 net loss per share of $0.30, widening from a loss of $0.28 a year earlier. Analysts polled by Capital IQ...
...
Health care stocks were leaning lower premarket Tuesday. The Health Care SPDR (XLV) was down 0.33% and the iShares NASDAQ Biotechnology Index (IBB) was...
Health care stocks were declining premarket Tuesday. The Health Care SPDR (XLV) was down 0.35% and the iShares NASDAQ Biotechnology Index (IBB) was...
Aldeyra Therapeutics (ALDX) said Tuesday its opthalmic solution candidate, reproxalap, for the treatment of dry eye disease was statistically superior to...
Price: 4.6, Change: +0.13, Percent Change: +2.91 ...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Aldeyra Therapeutics (ALDX) has an average rating of buy and price targets ranging from $11 to $30, according to analysts polled by Capital IQ. (MT...
Aldeyra Therapeutics (ALDX) said Wednesday that its late-stage clinical trial of reproxalap for the potential treatment of dry eye disease has met its...